Hopp til hovedinnhold

Blodpropp i leggen (DVT)

Blodpropp i vener rammer hvert år omtrent to av 1000 mennesker over 50 år. Det kan gi varierende grad av plager, men typisk er at det syke benet blir ømt, hovent og varmt.

Sist revidert:

QR
Del pasientinformasjon

Den ligger åpent tilgjengelig på NHI.no sammen annen relevant informasjon

https://nhi.no/sykdommer/hjertekar/blodproppsykdom/blodpropp-i-leggen-dvt/ 

Hva er dyp venetrombose?

Symptomer

Årsaker

Kvinner og blodpropp

Diagnostikk

Behandling

Akuttbehandling

Oppfølging

Forebyggende behandling

Prognose

Vil du vite mer?

Undervisningsprogram

Quiz

Illustrasjoner

Kilder

Referanser

Dette dokumentet er basert på det profesjonelle dokumentet Dyp venetrombose. Referanselisten for dette dokumentet vises nedenfor.

  1. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet 2005; 365: 1163-74. PubMed 
  2. Hansson PO, Welin L, Tibblin G, Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population. Arch Intern Med 1997; 157: 1665-70. PubMed 
  3. Silverstein MD et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism. A 25-year poplulation-based study. Arch Intern Med 1998; 158: 585-93. PubMed 
  4. Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 2008; 28: 360-2. PMID: 18296591 PubMed 
  5. Douketis J, Tosetto A, Marucci M, et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ 2011; 342: d813. PubMed 
  6. Apenteng PN, Hobbs FR, Roalfe A, et al. Incidence of venous thromboembolism in care homes: a prospective cohort study. Br J Gen Pract 2017 Feb; 67 (655): e130-e137. pmid:28093420 PubMed 
  7. Gavish I, Brenner B. Air travel and the risk of thromboembolism. Intern Emerg Med. 2010 Nov 6. Epub ahead of print.
  8. Watson HG and Baglin TP. Guidelines on travel-related venous thrombosis. BJH; 152: 31-34.
  9. Goldhaber SZ. Risk factors for venous thromboembolism. J Am Coll Cardiol. 2010; 56: 1-7. PubMed 
  10. Stanley A and Young A. Primary prevention of thromboembolism in medical and surgical oncology patients. BJC 2010; 102; 10-16.
  11. Zöller B, Xinjun L, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 2012; 379: 244-9 PubMed 
  12. Goel R, Patel EU, Cushing MM, et al. Association of Perioperative Red Blood Cell Transfusions With Venous Thromboembolism in a North American Registry. JAMA Surg 2018; 153: 826-33. pmid:29898202 PubMed 
  13. Chang S-L, Huang Y-L, Lee M-C, et al. Association of Varicose Veins With Incident Venous Thromboembolism and Peripheral Artery Disease. JAMA 2018; 319: 807-17. pmid: 29486040 PubMed 
  14. Walker RF, Zakai NA, MacLehose RF, et al. Association of Testosterone Therapy With Risk of Venous Thromboembolism Among Men With and Without Hypogonadism. JAMA Intern Med 2019. pmid:31710339 PubMed 
  15. Trigg DE, Wood MG, Koides PA et al.Hormonal Influences on Haemostasis in Women. Sem Thromb Haemost 2011; 37: 77-86 PubMed 
  16. Canonico M, Plu-Bureau G, Lowe GDO, Scarabin P-Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008; 336: 1227-31. British Medical Journal 
  17. Rodina MT, Pendleton R, Wheeler M, Rodgers GM. The treatment of venous thromboembolism in special populations Thrombosis Research 2007; 119: 391-402. PubMed 
  18. Stegeman BH, de Bastos M, Rosendaal FR, et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ 2013; 347: f5298. BMJ (DOI) 
  19. Laliberté F, Dea K, Duh MS, et al. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause 2011; 18: 1052-9. PubMed 
  20. Mantha S, Karp R, Raghavan V, et al. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ 2012; 345: e4944. BMJ (DOI) 
  21. Bernardi E, Camporese G, Büller HR et al. Serial 2-point ultrasonography plus D-dimer vs whole-leg color-coded doppler ultrasonography for diagnosing suspected symptomatic deep vein thrombosis. JAMA 2008; 300: 1653-9. PubMed 
  22. Kearon C , et al. A randomized trial of diagnostic strategies after normal proximal vein ultrasonography for suspected deep venous thrombosis: D-dimer testing compared with repeated ultrasonography. Ann Intern Med 2005; 142: 490-6. Annals of Internal Medicine 
  23. Goodacre S, Sutton AJ, Sampson FC. Meta-analysis: The value of clinical assessment in the diagnosis of deep vein thrombosis. Ann Intern Med 2005; 143: 129-39. PubMed 
  24. Garcia-Bolado A, Del Cura JL. CT venography vs ultrasound in the diagnosis of thromboembolic disease in patients with clinical suspicion of pulmonary embolism. Emerg Radiol. 2007;14:403–409.
  25. Pollak, AW, McBane, RD. Succinct review of the new VTE prevention and management guidelines. Mayo Clinic Proceedings 2014; 89, 3; 394-408
  26. Scarvelis D, Wells PS. Diagnosis and treatment of deep-vein thrombosis. CMAJ 2006; 175: 1087-92. pmid:17060659 PubMed 
  27. Wells PS, Anderson D, Rodger M et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Eng J med 2003; 349: 1227-35. New England Journal of Medicine 
  28. Bounemeaux H, Perrier A and Righini M. Diagnosis of venous thromboembolism: un update. Vasc Med 2010; 15: 399-406. PubMed 
  29. van der Velde EF, Toll DB, Ten Cate-Hoek AJ et al. Comparing the diagnostic performance of 2 clinical decision rules to rule out deep vein thrombosis in primary care patients. Ann fam Med 2011; 9: 31-6. PubMed 
  30. Silveira PC, Ip IK, Goldhaber SZ, et al. Performance of Wells score for deep vein thrombosis in the inpatient setting. JAMA Intern Med 2015; 175: 1112-7. DOI: 10.1001/jamainternmed.2015.1687 DOI 
  31. Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA 2014; 311: 1117-24. pmid:24643601 PubMed 
  32. Segal JB, Streiff MB, Hofmann LV, Thornton K, Bass EB. Management of venous thromboembolism: a systematic review for a practice guideline. Ann Intern Med 2007; 146: 211-22. PubMed 
  33. Huo MH and Spyropoulis AC. The eighth American college of chest phycisians guidelines on venous thromboembolism prevention: implications for hospital prophylaxis strategies. J Thromb Thrombolysis 2010 (e-pub ahead of print).
  34. Wittkowsky AK. New oral anticoagulants: a practical guide for clinicans. J Throm Thrombolysis 2010; 29: 182-191. PubMed 
  35. Kahn SR, Shapiro S, Wells PS, et al. Compression stockings to prevent post-thrombotic syndrome: a randomized placebo-controlled trial. Lancet 2013; doi:10/1016/S0140-6736(13)61902-9
  36. Berntsen CF, Kristiansen A, Akl EA, et al. Compression stockings for preventing the postthrombotic syndrome in patients with deep vein thrombosis. Am J Med. 2016. PMID: 26747198 PubMed 
  37. MazzolaI L, Aboyans V, Ageno W, et al . Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J 2018; 39: 4208-18. pmid:28329262 PubMed 
  38. Streiff MB, Agnelli G, Connors JM, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis 2016; 41: 32-67. pmid:26780738 PubMed 
  39. Vandvik PO, Kristiansen A, Brandt L, Berge E, Dahm AE, Halvorsen S, Sandset PM. Retningslinje for antitrombotisk behandling og tromboseprofylakse, 2013.
  40. Wells PS, Forgie MA, Rodger MA. Treatment of venous thromboembolism. JAMA 2014; 311:717-28. doi: 10.1001/jama.2014.65 DOI 
  41. Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood 2014; 123 (12): 1794-1801. doi: 10.1182/blood-2013-12-512681 DOI 
  42. Sterne JA, Bodalia PN, Bryden PA, et al. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess. 2017; 9: 1-386. PMID: 28279251 PubMed 
  43. Dahm AEA, Fetveit A, Schirmer H. Høringsutkast: Retningslinjer for antiotrombotisk behandling og profylakse - 2019. Siden lest 10.10.2019. app.magicapp.org 
  44. Lozano F, Trujillo-Santos J, Barrón M, et al. Home versus in-hospital treatment of outpatients with acute deep venous thrombosis of the lower limbs. J Vasc Surg 2014; 59: 1362-7. pmid:24439322 PubMed 
  45. Robertson L, Kesteven P, McCaslin JE. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. Cochrane Database Syst Rev. 2015 Jun 30;6:CD010956. doi: 10.1002/14651858.CD010956.pub2 DOI 
  46. Helsedirektoratet. Statens legemiddelverk. Informasjon om warfarin og de nye perorale antikoagulasjonsmidlene dabigatran, rivaroksaban og apixaban. IS-2050. Versjon 2.0. November 2013
  47. Dawwas GK, Leonard CE, Lewis JD, Cuker A. Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data. Ann Intern Med 2022; 175: 20-28. pmid:34871048 PubMed 
  48. Ghanima W, Atar D, Sandset PM. Nye perorale antikoagulasjonsmidler - en oversikt. Tidsskr Nor Legeforen 2013; 133: 1940-5. Tidsskrift for Den norske legeforening 
  49. Jun M, Lix LM, Durand M, et al. Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study. BMJ 2017. PMID: 29042362 PubMed 
  50. Reikvam Å og Sandset PM. Warfarinbehandling i praksis – Tryggere antikoagulasjon. Skriftserie for leger 2010 (ISBN-13 978-82-8070-083-4).
  51. Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021; 5: 927-74. pmid:33570602 PubMed 
  52. Agnelli G, Becattini C, Meyer G, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020 Apr 23;382(17):1599-1607. PMID: 32223112 PubMed 
  53. Raskob GE, van ES N, Verhamme P, et al. Edoxaban for the Treatment of CancerAssociated Venous Thromboembolism. N Engl J Med 2018; 378: 615-24. pmid:29231094 PubMed 
  54. Young AM, Marshall A, Thirlwall J, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol 2019; 36: 2017-23. pmid:29746227 PubMed 
  55. Fernandes CJ, Morinaga LTK, Alves Jr JL, et al. Cancer-associated thrombosis: the when, how and why. Eur Respir Rev 2019. pmid:30918022 PubMed 
  56. Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer‐associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 2018; 9: 1891-4. pmid:30027649 PubMed 
  57. Vandvik PO, Kristiansen A, Brandt L, Berge E, Dahm AE, Halvorsen S, Sandset PM. Retningslinje for antitrombotisk behandling og tromboseprofylakse, publisert des. 2016. www.magicapp.org 
  58. Ly B, Njaastad AM, Sandbæk G, Solstrand R, Rosales A, Slagsvold C-E. Kateterbasert trombolytisk behandling av bekkenvenetrombose. Tidsskr Nor Lægeforen 2004; 124: 478-80. PubMed 
  59. Watson L, Broderick C, Armon MP. Thrombolysis for acute deep vein thrombosis. Cochrane Database Syst Rev. 2014;1:CD002783. doi: 10.1002/14651858.CD002783.pub3. DOI 
  60. Vedantham S. Catheterdirected thrombolysis for deep vein thrombosis. Curr Opin hematol 2010; 17: 464-8. PubMed 
  61. Popuri RK, Vedantham S. The role of thrombolysis in the Clinical management of Deep Vein thrombosis. Arterioscler Thromb Vasc Biol 2011; 31: 479-484. PubMed 
  62. Enden T, Haig Y, Kløw N-E, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet 2011; : doi:10.1016/S0140-6736(11)61753-4. DOI 
  63. Goldenberg NA, Kittelson JM, Abshire TC, et al. Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism The Kids-DOTT Randomized Clinical Trial. JAMA 2022; 327: 129-37. pmid:35015038 PubMed 
  64. Khan F, Tritschler T, Kimpton M, et al. Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism A Systematic Review and Meta-analysis. Ann Intern Med 2021. pmid:34516270 PubMed 
  65. Simes J, Becattini C, Agnelli G, et al. Aspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration. Circulation. 2014 Sep 23;130(13):1062-71 PubMed 
  66. Amin EE, Bistervels IM, Meijer K, et al. Residual vein occlusion in relation to immediate compression and postthrombotic syndrome in deep vein thrombosis.. Blood 2018. pmid:30237155 PubMed 
  67. Bashir R, Zack CJ, Zhao H, et al. Comparative outcomes of catheter-directed thrombolysis plus anticoagulation vs anticoagulation alone to treat lower-extremity proximal deep vein thrombosis. JAMA Intern Med 2014. doi:10.1001/jamainternmed.2014.3415 DOI 
  68. Beccatini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366: 1959-67. New England Journal of Medicine 
  69. Brighton TA, Eikelbooom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012. doi:10.1056/NEJMoa1210384 DOI 
  70. Weitz JI, Lensing AW, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017. pmid:28316279 PubMed 
  71. Guyatt GH, Akl EA, Crowther M, et al. Executive summary: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141: 7S-47S. PubMed 
  72. Geerts WH, Bergqvist D, Pineo GF et al. Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: S381-S453.
  73. Ræder J og Nordentoft J. Dagkirurgi og anestesi. Tidsskr Nor Legeforen 2010; 130: 742-6. Tidsskrift for Den norske legeforening 
  74. Sachdeva A, Dalton M, Amaragiri SV, et al. Graduated compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev. 2014;12:CD001484. doi: 10.1002/14651858.CD001484.pub3. The Cochrane Library 
  75. ICM-VTE Hip & Knee Delegates. Recommendations from the ICM-VTE: Hip & Knee. J Bone Joint Surg Am 2022; 104: 180-231. pmid:35315610 PubMed 
  76. Anderson DR, Dunbar M, Murnaghan J, et al. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. N Engl J Med 2018; 378: 699-707. doi:10.1056/NEJMoa1712746 DOI 
  77. Testroote M, Stigter WA, Janssen L, et al. Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-leg immobilization. Cochrane Database Syst Rev. 2014 Apr 25;4:CD006681 Cochrane (DOI) 
  78. Gómes-Outes A, Terleira-Fernández AI, Suárez-Gea ML, Vargas-Castrillón E. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ 2012; 344: e3675. BMJ (DOI) 
  79. Caldeira D, Rodrigues FB, Barra M, et al. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart. 2015; doi: 10.1136/heartjnl-2015-307489 DOI 
  80. Li R, Yuan M, Cheng J, et al. Risk of post-thrombotic syndrome after deep vein thrombosis treated with rivaroxaban versus vitamin-K antagonists: A systematic review and meta-analysis published online ahead of print, 2020 Sep 17. Thromb Res. 2020;196:340-348. PMID: 32977134 PubMed 
  81. Reitter SE, Waldhoer T, Mayerhofer M et al. Long-term survival of patients with a history of venous thromboembolism. Ann Hematol Feb 2011 (online first).
  82. Carrier M, Le Gal G, Wells PS et al. Systematic review: case-fatality rates of recurrent Venous Thromboembolism and major Bleeding Events Among Patients treated for venous Thromboembolism. Ann Intern Med 2010; 152: 578-589. Annals of Internal Medicine 
  83. Eerenberg ES, Middeldorp S, Levi M, et al. Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. J Thromb Haemostat 2015; 13: 1590-6. pmid:26179293 PubMed 
  84. Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med 2017. doi:10.1056/NEJMoa1707278 DOI 
  85. Niessner A, Tamargo J, Morais J et al. Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. Eur Heart J 2017; 38: 1710 - 6. PMID: 26705385 PubMed 
  86. Rutherford O-CW, König MSS, Risnes K. Antidotbehandling ved bruk av direktevirkende antikoagulasjonsmidler. Tidsskr Nor Legeforen 2018. doi:10.4045/tidsskr.17.0190 DOI 
  87. Garry J, Duke A, Labropoulos N. Systematic review of the complications following isolated calf deep vein thrombosis. Br J Surg 2016; 103: 789-96. pmid:27060255 PubMed 
  88. Khan F, Rahman A, Carrier M, et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ 2019; 366: l4363. pmid:31340984 PubMed 
  89. Semb VB, Tveit A. Begrenset malignitetsutredning ved idiopatisk venøs trombose. Tidsskr Nor Legeforen 2014; 134: 407-11. doi:10.4045/tidsskr.13.0310 DOI 
  90. Husseinzadeh H, Carrier M. Occult cancer detection in patients with hemostatic disorder and venous thromboembolism. Thromb Res 2017. pmid:28587726 PubMed 
  91. Carrier M, Lazo-Langner A, Shivakumar S, et al. Screening for occult cancer in unprovoked venous thromboembolism. N Engl J Med. 2015. PMID: 26095467 PubMed 
  92. Ebraheem M, Alzahrani I, Crowther M, et al. Extended DOAC therapy in patients with VTE and potential risk of recurrence: a systematic review and meta-analysis. J Thromb Haemost. 2020. PMID: 32510840 PubMed 
  93. Righini M, Perrier A, De Moerloose P et al. D-dimer for venous thromboembolism diagnosis: 20 years later. J Tromb Haemost 2008; 6: 1059-1071. PubMed 
  94. Gaitini D. Multimodality imaging of the peripheral venous system. Int J Biomed Imaging ;2007:54616.
  95. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO; American College of Chest Physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e691S-736S
  96. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-52. PubMed 
  97. Akl EA, Rohilla S, Barba M, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review. Cancer 2008; 113: 1685-94. PubMed 
  98. Agnelli G, Becattini C, Meyer G, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med 2020; 382:1599. PMID: 31020211 PubMed 
  99. . . .